Access in all areas? A round up of developments in market access and health technology assessment: part 3
In this latest update, we explore some of the key updates in market access over recent months including the UK's voluntary scheme for branded medicines pricing, access and growth (VPAG), the first drugs funded by the Innovative Medicines Fund in the UK and the Direct Access Scheme in France, an...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Becaris Publishing Limited,
2024-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_afc97ac51a8b48b398a9a27ebcce3c5c | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Alice Beattie |e author |
| 700 | 1 | 0 | |a Catrin Treharne |e author |
| 700 | 1 | 0 | |a Sreeram V Ramagopalan |e author |
| 245 | 0 | 0 | |a Access in all areas? A round up of developments in market access and health technology assessment: part 3 |
| 260 | |b Becaris Publishing Limited, |c 2024-02-01T00:00:00Z. | ||
| 500 | |a 10.57264/cer-2024-0009 | ||
| 500 | |a 2042-6313 | ||
| 520 | |a In this latest update, we explore some of the key updates in market access over recent months including the UK's voluntary scheme for branded medicines pricing, access and growth (VPAG), the first drugs funded by the Innovative Medicines Fund in the UK and the Direct Access Scheme in France, and, finally, the new Institute for Clinical and Economic Review (ICER) value assessment framework in the USA. | ||
| 546 | |a EN | ||
| 690 | |a canadian drug agency | ||
| 690 | |a direct access scheme | ||
| 690 | |a health technology assessment | ||
| 690 | |a health technology management | ||
| 690 | |a icer | ||
| 690 | |a innovative medicines fund | ||
| 690 | |a market access | ||
| 690 | |a value assessment framework | ||
| 690 | |a vpag | ||
| 690 | |a Public aspects of medicine | ||
| 690 | |a RA1-1270 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Journal of Comparative Effectiveness Research, Vol 13, Iss 3 (2024) | |
| 787 | 0 | |n https://doaj.org/toc/2042-6313 | |
| 856 | 4 | 1 | |u https://doaj.org/article/afc97ac51a8b48b398a9a27ebcce3c5c |z Connect to this object online. |